Skip to main content

Table 1 Demographic, clinical, pathological, and surgical characteristics of the patients

From: Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy

Variables

Total population [n (%), n = 1593]

Development set [n (%), n = 1186]

Validation set [n (%), n = 407]

Age [median (IQRa)]

67.0 (57.0, 77.0)

68.0 (57.0, 77.0)

66.0 (55.0, 77.0)

 ≤65

715 (44.9)

520 (43.8)

195 (47.9)

 66–80

644 (40.4)

492 (41.5)

152 (37.3)

 > 80

234 (14.7)

174 (14.7)

60 (14.7)

Sex

 Male

1032 (64.8)

785 (66.2)

247 (60.7)

 Female

561 (35.2)

401 (33.8)

160 (39.3)

Race

 White

1014 (63.7)

763 (64.3)

251 (61.7)

 Black

240 (15.1)

181 (15.3)

59 (14.5)

 Other

339 (21.3)

242 (20.4)

97 (23.8)

Tumor location

 Cardia

269 (16.9)

213 (18.0)

56 (13.8)

 Non-cardia

998 (62.6)

738 (62.2)

260 (63.9)

 Overlapping lesion

182 (11.4)

128 (10.8)

54 (13.3)

 Stomach, NOSb

144 (9.0)

107 (9.0)

37 (9.1)

Tumor size (mm) [median (IQR)]

55.0 (40.0, 80.0)

55.0 (40.0, 80.0)

58.0 (40.0, 80.0)

 ≤30

230 (14.4)

172 (14.5)

58 (14.3)

 31–50

466 (29.3)

343 (28.9)

123 (30.2)

 >50

897 (56.3)

671 (56.6)

226 (55.5)

Pathological subtype

 Intestinal type

317 (19.9)

219 (18.5)

98 (24.1)

 Diffuse type

167 (10.5)

106 (8.9)

61 (15.0)

 Adenocarcinoma, NOS

959 (60.2)

754 (63.6)

205 (50.4)

 Other adenocarcinoma

150 (9.4)

107 (9.0)

43 (10.6)

Grade

 Grade1/2

425 (26.7)

311 (26.2)

114 (28.0)

 Grade3/4

1168 (73.3)

875 (73.8)

293 (72.0)

T stage (AJCCc 7th)

 T1

73 (4.6)

55 (4.6)

18 (4.4)

 T2

79 (5.0)

49 (4.1)

30 (7.4)

 T3

519 (32.6)

409 (34.5)

110 (27.0)

 T4a

577 (36.2)

402 (33.9)

175 (43.0)

 T4b

345 (21.7)

271 (22.8)

74 (18.2)

N stage (AJCC 7th)

 N0

202 (12.7)

142 (12.0)

60 (14.7)

 N1

706 (44.3)

522 (44.0)

184 (45.2)

 N2

458 (28.8)

349 (29.4)

109 (26.8)

 N3

227 (14.2)

173 (14.6)

54 (13.3)

Metastatic site(s)

 Distant LN(s)d

276 (17.3)

208 (17.5)

68 (16.7)

 Viscera

1121 (70.4)

839 (70.7)

282 (69.3)

 Viscera plus distant LN(s)

118 (7.4)

96 (8.1)

22 (5.4)

 Distant metastasis, NOS

78 (4.9)

43 (3.6)

35 (8.6)

Gastrectomy

 Partial gastrectomy

808 (50.7)

612 (51.6)

196 (48.2)

 Near-total or total gastrectomy

361 (22.7)

278 (23.4)

83 (20.4)

 Gastrectomy, NOS

424 (26.6)

296 (25.0)

128 (31.4)

No. of regional LN(s) examined [median (IQR)]

13 (6, 21)

12 (6, 20)

14 (7, 22)

 ≤10

660 (41.4)

518 (43.7)

142 (34.9)

 >10

933 (58.6)

668 (56.3)

265 (65.1)

Surgery to other site(s) or node(s)

 Yes

404 (25.4)

309 (26.1)

95 (23.3)

 No

1189 (74.6)

877 (73.9)

312 (76.7)

Chemotherapy

 Yes

802 (50.3)

579 (48.8)

223 (54.8)

 No/Unknown

791 (49.7)

607 (51.2)

184 (45.2)

Radiotherapy

   

 Yes

254 (15.9)

192 (16.2)

62 (15.2)

 No/Unknown

1339 (84.1)

994 (83.8)

345 (84.8)

Sequence of radiotherapy with surgery

 Pre-operative radiotherapy

69/254 (27.2)

37/192 (19.3)

32/62 (51.6)

 Post-operative radiotherapy

182/254 (71.7)

153/192 (79.7)

29/62 (46.8)

 Intraoperative or sandwich

3/254 (1.2)

2/192 (1.0)

1/62 (1.6)

  1. ainterquartile range; bnot otherwise specified; cAmerican Joint Committee on Cancer; dlymph node(s)